References

Compare Supplement Facts: Other brands include only vague descriptions of various extracts or opcs.

  • Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
  • Masquelier, J. A lifetime devoted to OPC and pycnogenol. Alfa Omega Editrice, Pub., 1996.
  • Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995.
  • Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997.
  • Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century. Warner Books, Inc., 1999.
  • Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985.
  • Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995.
  • Lieberman, S., et al. The real vitamin & mineral book: going beyond the RDA. Avery Pub., 1990.
  • ___. Inadequate intake of vitamins, particularly B-1, can result in mental illness. Clin. Neuro, 8 (Jul.--Sep. 1985):286-293.
  • ___. Carpal tunnel syndrome treated with riboflavin and pyridoxine. Proceedings of the Nat. Acad. of Sc. 81 (Nov. 1984):7076-8.
  • ___. High calorie diets with disproportionately low intakes of vitamins and minerals may be the source of widespread marginal malnutrition. Journ of the Amer Col of Nut, 7 (1988):61-67.
  • Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
  • Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
  • Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
  • Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969.
  • Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
  • Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
  • Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
  • Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
  • Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
    Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
  • Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504.
  • Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80.
  • Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
  • Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
  • Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all brain functions and counters Alzheimer’s disease: Keats Pub. 1998.
    Cenacchi T, et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 5: 123-133, 1993.
  • Maggioni M, Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 81: 265-270, 1990.
  • Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 34: 18-21, 1996.
  • Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43: 385-388, 1992.
  • Cenacchi T, et al., “Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.” Aging, 5, 123-133, 1993.
  • Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
  • Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, F.A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. Journal of the Amer Med Assoc, 278 (16):1327-32, 1997.
  • Waagepetersen, H.S., Sonnewald, U., Schousboe, A. The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem, 73:1335-42, 1999.
  • Goddard, A.W., Mason, G.F., Almai, A., Rothman, D.L., Behar, K.L., Petroff, O.A.C., Charney, D.S., Krystal, J.H. Reductions in occipital cortex gaba levels in panic disorder detected with h-magnetic resonance spectroscopy. Arch Gen Psychiatry, 58:556-561, 2001.
  • Braverman, E., et al. The healing nutrients within: in facts, findings and new research. Keats, 1987.
  • Cavagnini, F., et al. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinol, 93:149-54, 1980.
  • Bhagavan, H.N., et al. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics, 1975;55: 437-41.
  • ___. Along with riboflavin, vitamin B-6 deficiency has a primary role in the cause of emotional disorder. British Journal of Psychiatry, 141(1982):271-272.
  • ___. Current data suggest that as many as 20 percent of medically cleared population of outpatient depressives may suffer from a vitamin B-6 deficit. The authors point out that nutrition, diet and vitamin levels have received very little attention in the psychiatric literature. Biological Psychiatry, 9:4 (1984):613-6.
  • ___. Does depressive illness cause vitamin B-6 inadequacy, or vice-versa? Nut Rep Int, 27 (Apr. 1993):867-873.
  • Martineau, J., et al. Vit. B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Bio Psy, 20:467-78, 1985.
    Dolphin, et al. (eds). Vitamin B6: pyridoxal phosphate. John Wiley & Sons, 1986, chapt. 17.
  • Langseth, L., et al. Glucose tolerance and hyperkinesis. Food and Cosm Toxicology, 16 Aug. 1977.
  • O’Brien, C. Answers to ADD. Vitamin Retailer, March 2002.
    Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
  • Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
  • Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
  • Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of pycnogenol to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
  • Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
    Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
  • Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9.
  • Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15.
  • Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
  • Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
  • Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305.
  • Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
  • Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
  • Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980.
  • Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983.
  • Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
  • Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
  • Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
  • Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
  • Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989.
  • Masquelier, J. pycnogenol: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256.
    Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
  • Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93.
  • Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
  • Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999.
  • Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
  • Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
  • Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
  • Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83.
  • Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
  • Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
  • Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
  • Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988.
  • Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988.
  • Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988.
  • Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981.
  • Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
  • Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988.
  • Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
  • Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
  • Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
  • Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
  • Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984.
  • Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
  • Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972.
  • Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
  • Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
  • Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61.
  • Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
    Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999.
  • Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports People.
  • Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990.
  • Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
  • Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract submitted to national meeting of the Amer College of Sports Medicine, June 1998.
  • Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm 43: 385-388, 1992.
  • Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998.
  • Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976.
  • Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
  • Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306
  • Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082.
  • Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
  • Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235.
  • Masquelier, J., et al. “Flavonoids et pycnogenol” Int J Vit Nut Res, (49)3:307-311, 1979.
  • Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987.
  • Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971.
  • Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
    Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989.
  • Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971.
  • Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.

Flavay
for a healthy mind & body

Healthy Source
Protected by U.S. PATENT NO. 4,698,360 and international patents.
© Healthy Source, LP. All Rights Reserved. Legal Notices. Privacy Policy.
Statements made herein have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.